publication date: Oct. 4, 2017
NCI CTEP-Approved Trials for July
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Phase II 10021
A Phase II Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Dana-Farber – Harvard Cancer Center LAO
Schoenfeld, Jonathan Daniel
Phase II 10042
A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases
Yale University Cancer Center LAO
Goldberg, Sarah B.
Phase III NRG-BN003
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Rogers, C. Leland
(801) 359-8956 X 102
Phase Other AALL17B4-Q
Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia
Children’s Oncology Group
Carroll, William L.
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.